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ABSTRACT
Aims We aimed to evaluate the prognostic value of
routine use of PCR ampliﬁcation of immunoglobulin
gene rearrangements in bone marrow (BM) staging in
patients with follicular lymphoma (FL).
Methods Clonal rearrangements were assessed by
immunoglobulin heavy and light-chain gene
rearrangement analysis in BM aspirates from 96 patients
diagnosed with FL and related to morphological
detection of BM involvement in biopsies. In 71 patients,
results were also compared with concurrent ﬂow
cytometry analysis.
Results BM involvement was detected by PCR in
34.4% (33/96) of patients. The presence of clonal
rearrangements by PCR was associated with advanced
clinical stage (I–III vs IV; p<0.001), high FL International
Prognostic Index (FLIPI) score (0–1, 2 vs ≥3; p=0.003),
and detection of BM involvement by morphology and
ﬂow cytometry analysis (p<0.001 for both). PCR-positive
patients had a signiﬁcantly poorer survival than PCR-
negative patients (p=0.001, log-rank test). Thirteen
patients positive by PCR but without morphologically
detectable BM involvement, had signiﬁcantly poorer
survival than patients with negative morphology and
negative PCR result (p=0.002). The poor survival
associated with BM involvement by PCR was
independent of the FLIPI score (p=0.007, Cox
regression). BM involvement by morphology or ﬂow
cytometry did not show a signiﬁcant impact on survival.
Conclusions Our results showed that routine use of
PCR-based clonality analysis signiﬁcantly improved the
prognostic impact of BM staging in patients with FL. BM
involvement by PCR was also an independent adverse
prognostic factor.
INTRODUCTION
Bone marrow (BM) examination is routinely per-
formed in the staging of B-cell lymphoma. The
presence of BM involvement results in a clinical
stage IV classiﬁcation, is associated with less favour-
able prognosis, and may inﬂuence treatment deci-
sions.1–6 The BM is involved in 40%–70% of
follicular lymphoma (FL) cases.7 8
Diagnosis of BM involvement has traditionally
been based on morphological ﬁndings, but the
evaluation by morphological features has limita-
tions. BM involvement is frequently patchy, and it
is not always possible to obtain optimal biopsies in
routine practice. In addition to low sensitivity, it is
often difﬁcult to distinguish benign lymphoid
aggregates composed of small lymphoid cells from
inﬁltrates of malignant lymphoma.9–11 This
problem is especially common in BM biopsies
acquired from elderly patients, the age group with
the highest incidence of both benign lymphoid
aggregates and B-cell lymphomas.12 13
The BIOMED-2 multitarget PCR approach has
improved clonality testing and is increasingly used in
the diagnostics of B-cell malignancies. The highest
detection rates (>98%) are reached with the com-
bined use of immunoglobulin heavy (IGH) and κ
light (IGK) chains analyses.14–16 However, there have
been few reports evaluating the use of BIOMED-2
primers in BM staging and only one of these reports
included IGK analysis.17–19 Furthermore, there have
been only occasional studies attempting to correlate
PCR results with clinical outcome,18–21 and none of
these focused on FL.
In the present study, we have therefore evaluated
the contribution and prognostic value of
PCR-based clonality in BM staging of FL using
BIOMED-2 primers.
MATERIALS AND METHODS
Patient selection
All patients with FL (n=96) who had a BM aspirate
and a BM biopsy obtained at diagnosis in the period
between March 2003 and July 2011 at Haukeland
University Hospital, Bergen, were included in the
study. Diagnoses of FL (grades 1–3B) were based on
morphological and immunohistochemical assessment
of formalin-ﬁxed, parafﬁn-embedded (FFPE) tumour
biopsies from lymph nodes and extranodal sites, and
were classiﬁed in accordance with the 2008 WHO
classiﬁcation of lymphoid malignancies.22 Clinical
information including treatment and survival data
was collected from medical records. Clinical stage,
according to the Ann Arbor system, was determined
on ﬁndings from computed tomographic scans of the
neck, thorax, abdomen and pelvis as well as the BM
biopsy. Patients were assigned to speciﬁc risk groups
according to the FL International Prognostic Index
(FLIPI).2 The study was approved by the Regional
Committee for Medical and Health Research Ethics
(2013/211) and performed in accordance with the
Declaration of Helsinki.
BM morphology
BM biopsies were ﬁxed in 4% formalin, decalciﬁed
overnight in EDTA (75 mg/mL), embedded in paraf-
ﬁn, sectioned and stained with H&E. The mean
biopsy length was 14.5 mm with a range of
5–31 mm. Routine immunohistochemical stains
included CD20, CD3, κ and λ immunoglobulin light
chain stains, and were performed on a Dako
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Autostainer (Dako, Glostrup, Denmark). All BM biopsies were
examined by experienced haematopathologists in routine practice
and the original reports of BMmorphology were used.
PCR-based clonality
DNA was extracted from BM aspirates and from FFPE tissue of
the initial tumours in patients with a clonal result obtained in the
BM (n=33). The fresh aspirates were collected in EDTA (1.8 mg/
mL) and lymphocytes were isolated using Fiqoll-Paque PLUS
medium (GE Healthcare, Little Chalfont, Buckinghamshire, UK).
From FFPE tissue, two 10 mm sections were deparafﬁnised with
xylene and dehydrated in alcohol. Isolated lymphocytes and
deparafﬁnised tissue were digested overnight with proteinase K
(20 mg/mL). DNA was prepared manually using the EZNA
Tissue DNA kit according to the manufacturer’s instructions
(Omega Bio-Tek, Norcross, Georgia, USA).
PCR analyses were performed using BIOMED-2 primers as
previously described.14 23 The Vн-FR3-Jн primers were used in
all BM aspirates, whereas Vн-FR2-Jн primers were used in 93
and the Vκ-Jκ primers in 94 owing to limited amounts of DNA.
In nine aspirates, in which the three primer sets were negative
and BM morphology was positive, analysis with the Vн-FR1-Jн
and VK/intron-Kde primers was added. The choice of primers
was based on our previous analyses on FFPE FL samples
showing detection rates of 91.5% and 94.9% for the three-
primer and ﬁve-primer combinations, respectively.23 PCR
products were subjected to fragment analysis on an ABI 3100
capillary sequencer (Applied Biosystems, Foster City, California,
USA). Clonality was determined by the presence of one or two
distinct peaks within the expected size range.
Flow cytometry
Reports on concurrent immunophenotyping of BM aspirates
were retrieved from laboratory records of 71 patients. Eleven
analyses were performed on a four-colour Coulter Epics XL ﬂow
cytometer (Beckman Coulter, Brea, California, USA) and 60 ana-
lyses on an eight-colour FACSCanto II ﬂow cytometer (Becton
Dickinson, Franklin Lakes, New Jersey, USA). Flow cytometric
two-parameter dot plots and quadrant statistics were generated
by Cellquest software (Becton-Dickinson Immunocytometry
Systems). All 71 samples were tested for expression of CD5,
CD10, CD11c, CD19, CD20, CD22, CD23, CD45 and κ and λ
light chains. For most samples, clonality was deﬁned as light
chain restriction with a κ:λ ratio of >3:1 or <0.3:1. These
cut-off values were not used, or used with great care, in patients
with low amounts of CD19+/CD20+/CD45+ cells. Clonal
samples or samples evaluated as being suspect for clonality were
tested for the expressiom of the additional markers CD25,
CD31, CD38, CD43, CD79b, CD81, CD103, CD200, HLA-DR
and LAIR1.
Statistical analysis
The Pearson’s χ2 and Fisher’s exact tests were performed to
compare categorical variables. Survival curves of time to death
due to lymphoma were estimated using the product-limit pro-
cedure (Kaplan–Meier method) with date of histological diagno-
sis as starting point. Differences between categories were
estimated by log-rank statistics. Patients who died of other
causes than lymphoma were treated as censored observations.
Median follow-up time was estimated by the reversed Kaplan–
Meier method. Univariate and multivariate analyses were
performed with the Cox proportional hazards method. The
variables were tested by a log-log plot, and the proportionally
assumption did not seem to be violated. Backward and forward
selections of variables were performed to determine the vari-
ables ability to be incorporated in multivariate models. All
results were considered signiﬁcant if p≤0.05. SPSS V.21.0 (SPSS,
Chicago, Illinois, USA) was used for all statistical analyses.
RESULTS
Clinical characteristics
The patients’ ages ranged from 33 to 82 years (median 61 years).
Treatment data were available for all patients. Fifty-eight patients
were initially treated with cyclophosphamide, hydroxydaunorubi-
cin, oncovin and prednisolone (CHOP) or COP. Rituximab was
added in 55 and radiation therapy was applied as consolidation in
17 of these patients. Nine patients received chlorambucil. Fifteen
patients with stage I or II and grade 1 or 2 FLs were treated with
local radiation therapy. Fourteen patients were observed. Median
follow-up time for the patients was 61 months.
BM involvement by morphology and PCR-based clonality
BM involvement was reported in 30.2% (29/96) of BM biop-
sies. Characteristic CD20-positive paratrabecular inﬁltrates were
described in all these biopsies.
BM involvement was detected by PCR-based clonality in 34.4%
(33/96) of BM aspirates. FFPE tissue from the primary tumour
showed identically sized clonal rearrangement in 31 of these cases.
In two cases, the PCR product from the primary tumour consisted
of few ampliﬁed fragments of small size (<250 bp) and was consid-
ered insufﬁcient for the detection of clonality.
Thirteen cases without morphologically detectable BM
involvement were positive by PCR. Representative images of
BM biopsies in two cases that were negative by morphology and
in which PCR was positive or negative, are shown in ﬁgure 1.
Frequencies of PCR-positive aspirates in relation to FL grade,
BM involvement by morphology and clinical variables studied
for all 96 patients are shown in table 1. The presence of
PCR-based clonality in aspirates was associated with morpho-
logical detection of BM involvement (p<0.001), clinical stage
IV (p<0.001) and FLIPI score ≥3 (p=0.003).
BM involvement by ﬂow cytometry
BM involvement by ﬂow cytometry was reported in 23.9%
(17/71) of patients (table 2). There was a signiﬁcant association
between BM involvement detected by ﬂow cytometry and by
morphology (p=0.004) or by PCR (p<0.001).
Prognostic signiﬁcance of BM involvement
The estimated survival at 60 months for patients with and
without BM involvement by PCR was 81.3% (SE 6.9%) and
97.7% (SE 2.3%). PCR-positive patients had a signiﬁcantly
poorer survival than PCR-negative (p=0.001, ﬁgure 2A),
whereas, involvement by morphology showed no signiﬁcant
impact on survival (p=0.742, ﬁgure 2B). The HR for BM
involvement by PCR was estimated at 8.23 (95% CI 1.77 to
38.32) and at 5.42 (95% CI 1.16 to 25.31) when used in addi-
tion to morphology (table 3).
The estimated survival at 60 months for patients with nega-
tive BM morphology and negative PCR was 97.3% (SE 2.7%),
for patients with positive BM morphology 88.5% (SE 6.3%)
and for patients with negative BM morphology and positive
PCR 76.9% (SE 11.7%). The last group of patients had a signiﬁ-
cantly poorer survival than the ﬁrst (p=0.002, ﬁgure 2C). The
same results were obtained, when survival analysis was per-
formed after exclusion of the two patients with BM involvement
by PCR and in whom diagnostic tumour biopsies were not eva-
luable by PCR-based clonality analysis.
Berget E, et al. J Clin Pathol 2014;67:1072–1077. doi:10.1136/jclinpath-2014-202382 1073
Original article
group.bmj.com on December 29, 2014 - Published by http://jcp.bmj.com/Downloaded from 
Seventy-one patients had performed concurrent ﬂow cyto-
metric immunophenotyping. BM involvement by ﬂow cytome-
try did not show statistically signiﬁcant impact on survival
neither when used alone nor in addition to morphology
(p=0.143 and p=0.160, respectively, table 4).
FLIPI score and multivariate analysis
Signiﬁcantly poorer survival was observed in patients with high
FLIPI score (≥3) as compared with patients with low or inter-
mediate FLIPI scores (p=0.017, table 3). Presence of BM
involvement by PCR was an independent prognostic factor by
multivariate analysis (HR 9.34, 95% CI 1.85 to 47.30,
p=0.007) when high FLIPI score (≥3) was incorporated
(table 5). When PCR was used as a prognostic factor in addition
to BM morphology, the HR was 4.79 (95% CI 0.99 to 23.07,
p=0.051) in the multivariate model (data not shown).
DISCUSSION
We have evaluated the performance of routine use of
PCR-based immunoglobulin rearrangement analysis in the diag-
nosis of BM involvement in FL.
A variety of approaches have been used for the detection of
B-cell clonality in BM staging,17 18 20 21 24–30 and most previous
studies have used consensus primers against framework region 3
or framework region 2 of the IGH gene.20 24–30 Using
BIOMED-2 primers, we detected BM involvement by
PCR-based clonality in 13 patients without morphologically
detectable BM involvement. To our knowledge, this is the ﬁrst
study evaluating the prognostic value of PCR-based clonality in
BM staging of patients with FL. PCR-positive cases had a signiﬁ-
cantly poorer survival than PCR-negative, and the presence of
BM involvement by PCR was also an independent prognostic
factor by multivariate analysis. Furthermore, patients with posi-
tive PCR but without morphologically detectable BM involve-
ment had a signiﬁcantly poorer survival than patients who were
negative by both PCR and morphology.
By contrast, BM involvement by morphology was not a sig-
niﬁcant predictor of poor survival in our study. There are con-
ﬂicting reports regarding the prognostic impact of BM
involvement in patients with FL. BM involvement by morph-
ology has been associated with decreased survival in several
investigations including those of the FLIPI studies.2 5 Others
have found the morphological pattern or degree of involvement
rather than BM involvement by itself to affect survival.8 31 32 In
our study, the evaluation of involvement by morphology was
based on the original pathology reports, and morphological BM
involvement (30.2%) was somewhat lower than previously
reported for FL cases.7 8 We, therefore, reviewed the BM biop-
sies of all PCR-positive cases with negative pathology reports.
Of the 13 cases, ﬁve showed no lymphoid aggregates, whereas,
eight showed one or two small lymphoid aggregates. These
were predominantly composed of small CD20–positive cells and
only in two cases a paratrabecular localisation could be seen.
Thus, the relatively low fraction of BM involvement by morph-
ology could not, in general, be explained by wrong classiﬁcation
in the original reports. The insigniﬁcant prognostic impact of
BM involvement by morphology in our study may reﬂect that
minimal changes not always can be detected by conventional
methods, as also observed by others.9–11 33
We also performed a histology review of the nine cases that
had positive BM involvement by morphology, but were negative
by PCR in the aspirates. Four biopsies showed one or two small
Figure 1 Images from two follicular lymphoma cases, where bone marrow (BM) biopsies were reported negative for morphological BM
involvement. PCR was negative in the case of the upper panel and positive in the case of the lower panel. The images show H&E stained sections
(left) and immunohistochemistry by CD20 (right). Magniﬁcation ×400.
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paratrabecular lymphoid aggregates, three exhibited several
paratrabecular lymphoid aggregates and two had densely packed
marrows with tumour cells. Possible explanations for the nega-
tive PCR results in these cases may be related to the frequency
of somatic hypermutations in FL that hamper binding efﬁciency
of primers. Furthermore, a clonal rearrangement, identically
sized to that of the primary tumour, was achieved in the corre-
sponding BM biopsy in one of these cases, suggesting that false
negative PCR results also might be related to the inadequacy of
sampled aspirates.
Notably, PCR-based BM involvement showed a strong prog-
nostic impact, even when this analysis in some cases did not
detect deﬁnite BM involvement as judged by morphology. This
Table 1 Clinicopathological factors according to the detection of
BM involvement by PCR-based clonality in 96 cases of follicular
lymphoma
PCR-based clonality
Variables n
No involvement
(%)
Involvement
(%) p Value*
Sex
Female 59 36 (61.0) 23 (39.0)
Male 37 27 (73.0) 10 (27.0) 0.230
Age (years)
≤60 42 30 (71.4) 12 (28.6)
>60 54 33 (61.1) 21 (38.9) 0.291
WHO grade
1 35 20 (57.1) 15 (42.9)
2 30 21 (70.0) 9 (30.0)
3A and 3B 31 22 (71.0) 9 (29.0) 0.447 (1, 2 vs 3)
BM morphology
No involvement 67 54 (80.6) 13 (19.4)
Involvement 29 9 (31.0) 20 (69.0) <0.001
Clinical stage
I 16 14 (87.5) 2 (12.5)
II 16 16 (100.0) 0 (0.0)
III 34 24 (70.6) 10 (29.4)
IV 30 9 (30.0) 21 (70.0) <0.001 (I–III vs IV)
FLIPI score
Low (0–1) 45 37 (82.2) 8 (17.8)
Intermediate (2) 23 14 (60.9) 9 (39.1)
High (≥3) 28 12 (42.9) 16 (57.1) 0.003 (0–2 vs ≥3)
*Pearson’s χ2 test.
BM, bone marrow; FLIPI, Follicular Lymphoma International Prognostic Index.
Figure 2 Kaplan–Meier survival curves of patients with follicular
lymphoma according to the presence of bone marrow (BM)
involvement by PCR-based clonality (A) and by morphology (B). (C),
Survival curves of BM involvement by morphology, and to the presence
of PCR-based clonality without morphologically detectable BM
involvement. Statistical differences were calculated by the log-rank test.
Neg, negative; pos, positive.
Table 2 Comparison of bone marrow (BM) involvement by flow
cytometry, morphology and PCR-based clonality in the 71 cases
with results from immunophenotyping of aspirates
BM involvement N
Flow cytometry analysis
P value*No involvement (%) Involvement (%)
Morphology
No involvement 49 42 (85.7) 7 (14.3)
Involvement 22 12 (54.5) 10 (45.5) 0.004
PCR
No involvement 45 43 (95.6) 2 (4.4)
Involvement 26 11 (42.3) 15 (57.7) <0.001
Morphology and/or PCR
No involvement 39 38 (97.4) 1 (2.6)
Involvement 32 16 (50.0) 16 (50.0) <0.001
*Pearson’s χ2 or Fisher’s exact test, where appropriate.
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would indicate that PCR detects an additional group of patients
with BM involvement and severe prognosis. We have considered
the possibility that the PCR-positive, morphology-negative
patients could have received different therapy than the other
groups, but did not observe any obvious treatment differences
when reviewing their medical records. Another explanation
could be that PCR might have detected blood involvement
instead of BM involvement. A review of the medical records
showed that none of the 13 morphology-negative, PCR-positive
patients had detectable leukaemic phase by standard blood tests.
However, this does not exclude that PCR, at least in some cases,
did detect circulating lymphoma cells, which could have contrib-
uted to the observed adverse prognosis.
Seventy-one of our patients with FL had performed concur-
rent ﬂow cytometry, which turned out to be the least sensitive
method for detection of BM involvement. There was no signiﬁ-
cant difference in survival using ﬂow cytometry analysis alone
or in addition to morphology. Our results were in accordance
with several previous studies showing that ﬂow cytometry ana-
lysis underestimates the extent of BM involvement with respect
to morphology in BM staging of FL, possibly because of the
predominantly paratrabecular inﬁltration typical for FL
cases.34–39 However, the discrepant results with respect to PCR
cannot easily be explained by the method of sampling. Further
development of multicolour ﬂow cytometry may lead to
increased sensitivity of this technique.
In conclusion, although validation in larger series is war-
ranted, our data suggest an important contribution of
PCR-based clonality analysis in BM staging of patients with FL.
The prognostic value of BM staging was improved by perform-
ing PCR analysis, and BM involvement by PCR was also an
adverse prognostic factor independent of high FLIPI score. It
should be emphasised that our results do not indicate that
PCR-based clonality analysis of BM aspirates can replace mor-
phological examination of BM biopsies, but rather support the
inclusion of PCR in routine BM staging of FL.
Take home messages
▸ The prognostic value of bone marrow staging in follicular
lymphoma was improved by PCR-based clonality analyses.
▸ Bone marrow involvement by PCR predicts a poor clinical
outcome independent of high FL International Prognostic
Index score.
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Table 3 Survival studies by univariate Cox’s regression analysis in
96 cases of follicular lymphoma
Variables n HR 95% CI p Value*
Sex
Female 59 1
Male 37 1.923 0.568 to 6.536 0.285
Age (years)
≤60 42 1
>60 54 3.316 0.715 to 15.387 0.104
WHO grade
Grades 1 and 2 65 1
Grade 3A and 3B 31 1.050 0.566 to 1.951 0.876
BM morphology
No involvement 67 1
Involvement 29 1.232 0.356 to 4.262 0.742
Clinical stage
I–III 66 1
IV 30 1.070 0.786 to 1.457 0.667
FLIPI score
Low and intermediate (0–1, 2) 68 1
High (≥3) 28 3.994 1.164 to 13.700 0.017
BM by PCR
No involvement 63 1
Involvement 33 8.232 1.768 to 38.322 0.001
BM by morphology and/or PCR
No involvement 54 1
Involvement 42 5.423 1.162 to 25.313 0.016
*Log-rank test.
BM, bone marrow; FLIPI, Follicular Lymphoma International Prognostic Index.
Table 4 Survival studies by univariate Cox’s regression analysis
according to bone marrow (BM) involvement in the 71 patients with
results from immunophenotyping of aspirates
BM involvement N HR 95% CI p Value*
Flow cytometry analysis
No involvement 54 1
Involvement 17 2.581 0.690 to 9.661 0.143
Morphology and/or flow cytometry analysis
No involvement 42 1
Involvement 29 2.683 0.639 to 11.274 0.160
Morphology and/or flow cytometry analysis and/or PCR
No involvement 38 1
Involvement 33 8.519 1.043 to 69.605 0.016
*Log-rank test.
Table 5 Multivariate Cox’s regression analysis of prognostic
factors in 96 cases of follicular lymphoma
Variables HR 95% CI p Value
Male sex 3.279 0.803 to 13.333 0.098
Age >60 years 2.749 0.578 to 13.064 0.203
FLIPI score ≥3 1.971 0.528 to 7.352 0.313
BM involvement by PCR 9.342 1.845 to 47.304 0.007
BM, bone marrow; FLIPI, Follicular Lymphoma International Prognostic Index.
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